According to BIS Research, Antibody Conjugate Oligonucleotides (ACOs) combine the gene-modulating properties of ...

Developed by ALX Oncology's protein engineers utilizing the Company's proprietary topoisomerase I inhibitor payload and ...

May 19, 2025Compugen Ltd. misses on earnings expectations. Reported EPS is $-0.08 EPS, expectations were $-0.06. Operator: ...

Pharmacokinetic and safety data from healthy volunteers anticipated around YE 2025 On track to initiate a Phase 2 study in 1H 2026 ORKA-002 preclinical data demonstrate the potential for dosing two to ...

Pfizer has joined the ranks of companies developing cancer drugs that target both PD-1 and VEGF – one of the hottest drug ...

Under terms of the deal, Pfizer will gain rights to develop, manufacture, and commercialize SSGJ-707 outside of China.

ATG-022 is Antengene's CLDN18.2 antibody-drug conjugate; KEYTRUDA® (pembrolizumab) is MSD's anti-PD-1 therapy.

Bone is not the inert structure we often imagine. It's alive, adapting daily to load-bearing and impact. But with over 200 ...

Pfizer jumps into cancer-treatment race with a $6 billion licensing deal with a China-based company, six months after Merck’s ...

International Conference, AstraZeneca presented results on its interleukin-33 (IL-33) inhibitor, tozorakimab, from its ...

ProCap Acquisition Corp (the "Company") announced today the pricing of its upsized initial public offering of 22,000,000 units at a price of $10.00 per unit. The units are expected to be listed on The ...